FDA Shifts to Single-Trial Default for Drug Approvals to Accelerate Market Entry

Key Facts

1The FDA announced that its new default standard for drug approvals will be a single clinical trial instead of two.

2The two-study standard dates back to the early 1960s, though the agency has exercised flexibility in fields like oncology in recent years.

3The reform is being rolled out alongside an initiative to collect robust post-market data on drugs and devices.

The U.S. Food and Drug Administration (FDA) has announced a landmark shift in its regulatory framework, moving to a single clinical trial as the default standard for drug approvals. This policy change replaces the long-standing requirement of two pivotal studies, a standard that has been in place since the early 1960s. The reform aims to streamline the approval process, significantly reducing research and development costs while accelerating the delivery of new treatments to patients. To balance this expedited process, the FDA is launching an initiative to collect more robust post-market data on drugs and medical devices. Industry experts view this move as a major catalyst for the biotech and pharmaceutical sectors, as it lowers barriers to entry for innovative therapies. Consequently, market sentiment remains bullish for healthcare-focused instruments such as XBI and XLV, reflecting the potential for faster commercialization cycles.